KANGLITAI BIOMEDICAL (QINGDAO) CO., LTD

Main purpose: To evaluate the safety and tolerability of KLT-1101 combined with Teplizumab injection in patients with melanoma and other solid tumors; Secondary purpose: To evaluate the preliminary efficacy of KLT-1101 combined with Teplizumab injection in patients with melanoma and other solid tumors; To evaluate the pharmacokinetic (PK) characteristics of KLT-1101 combined with Teplizumab injection in patients with melanoma and other solid tumors; To evaluate the immunogenicity of KLT-1101 combined with Teplizumab injection in patients with melanoma and other solid tumors; Exploratory purpose: To explore the correlation between drug exposure level and safety of KLT-1101 combined with Teplizumab injection; To explore the relationship between KLT-1101 and Teplizumab injection in patients with melanoma and other solid tumors; Combined PK/PD with Teplizumab injection to find the correlation between exposure concentration and effector cytokines; Evaluate the changes in biomarkers related to the anti-tumor efficacy of KLT-1101 combined with Teplizumab injection over time in patients with melanoma and other solid tumors; Evaluate the correlation between drug exposure level and anti-tumor efficacy of KLT-1101 combined with Teplizumab injection; Determine the phase II recommended dose (RP2D) of KLT-1101 combined with Teplizumab injection in patients with melanoma and other solid tumors;